questionsmedicales.fr
Tumeurs
Tumeurs par type histologique
Leucémies
Leucémies : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Leucémies : Questions médicales les plus fréquentes",
"headline": "Leucémies : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Leucémies : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-29",
"dateModified": "2025-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Leucémies"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs par type histologique",
"url": "https://questionsmedicales.fr/mesh/D009370",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs par type histologique",
"code": {
"@type": "MedicalCode",
"code": "D009370",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie myéloïde",
"alternateName": "Leukemia, Myeloid",
"url": "https://questionsmedicales.fr/mesh/D007951",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie myéloïde",
"code": {
"@type": "MedicalCode",
"code": "D007951",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe myéloïde",
"alternateName": "Leukemia, Myeloid, Acute",
"url": "https://questionsmedicales.fr/mesh/D015470",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe myéloïde",
"code": {
"@type": "MedicalCode",
"code": "D015470",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë à basophiles",
"alternateName": "Leukemia, Basophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015471",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë à basophiles",
"code": {
"@type": "MedicalCode",
"code": "D015471",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.125"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe à éosinophiles",
"alternateName": "Leukemia, Eosinophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015472",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe à éosinophiles",
"code": {
"@type": "MedicalCode",
"code": "D015472",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe mégacaryoblastique",
"alternateName": "Leukemia, Megakaryoblastic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007947",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe mégacaryoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007947",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe monoblastique",
"alternateName": "Leukemia, Monocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007948",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe monoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007948",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.484"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë promyélocytaire",
"alternateName": "Leukemia, Promyelocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015473",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë promyélocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015473",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.700"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë à basophiles",
"alternateName": "Leukemia, Basophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015471",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë à basophiles",
"code": {
"@type": "MedicalCode",
"code": "D015471",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.125"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe à éosinophiles",
"alternateName": "Leukemia, Eosinophilic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015472",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe à éosinophiles",
"code": {
"@type": "MedicalCode",
"code": "D015472",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe mégacaryoblastique",
"alternateName": "Leukemia, Megakaryoblastic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007947",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe mégacaryoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007947",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe monoblastique",
"alternateName": "Leukemia, Monocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D007948",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe monoblastique",
"code": {
"@type": "MedicalCode",
"code": "D007948",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.484"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aiguë promyélocytaire",
"alternateName": "Leukemia, Promyelocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015473",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aiguë promyélocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015473",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.275.700"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Leucémie aigüe myélomonocytaire",
"alternateName": "Leukemia, Myelomonocytic, Acute",
"url": "https://questionsmedicales.fr/mesh/D015479",
"about": {
"@type": "MedicalCondition",
"name": "Leucémie aigüe myélomonocytaire",
"code": {
"@type": "MedicalCode",
"code": "D015479",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.557.337.539.520"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Leucémies",
"alternateName": "Leukemia",
"code": {
"@type": "MedicalCode",
"code": "D007938",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Kumaran Mudaliar",
"url": "https://questionsmedicales.fr/author/Kumaran%20Mudaliar",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology and Laboratory Medicine Loyola University Medical Center Maywood Illinois USA."
}
},
{
"@type": "Person",
"name": "Gregor Eisenwort",
"url": "https://questionsmedicales.fr/author/Gregor%20Eisenwort",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Irina Sadovnik",
"url": "https://questionsmedicales.fr/author/Irina%20Sadovnik",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Alexandra Keller",
"url": "https://questionsmedicales.fr/author/Alexandra%20Keller",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
},
{
"@type": "Person",
"name": "Daniela Berger",
"url": "https://questionsmedicales.fr/author/Daniela%20Berger",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Circulating Immune Complexes and Complement Activation in Sensitized Kidney Transplant Recipients.",
"datePublished": "2024-10-10",
"url": "https://questionsmedicales.fr/article/39456685",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms252010904"
}
},
{
"@type": "ScholarlyArticle",
"name": "Tear fluid and complement activation products in tears after ocular surgery.",
"datePublished": "2023-07-18",
"url": "https://questionsmedicales.fr/article/37464366",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12886-023-03037-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis.",
"datePublished": "2023-02-24",
"url": "https://questionsmedicales.fr/article/36752022",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.15730"
}
},
{
"@type": "ScholarlyArticle",
"name": "Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.",
"datePublished": "2023-08-09",
"url": "https://questionsmedicales.fr/article/37622108",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1213920"
}
},
{
"@type": "ScholarlyArticle",
"name": "What complements complement in transplant-associated thrombotic microangiopathy?",
"datePublished": "2022-08-09",
"url": "https://questionsmedicales.fr/article/35942659",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/bjh.18402"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par type histologique",
"item": "https://questionsmedicales.fr/mesh/D009370"
},
{
"@type": "ListItem",
"position": 4,
"name": "Leucémies",
"item": "https://questionsmedicales.fr/mesh/D007938"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Leucémies - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Leucémies",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Leucémies",
"description": "Comment diagnostique-t-on une leucémie ?\nQuels tests sont utilisés pour confirmer une leucémie ?\nQuels signes indiquent une leucémie lors des tests ?\nLes examens d'imagerie sont-ils nécessaires ?\nQuelle est l'importance de la biopsie médullaire ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Complement+Activation&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Leucémies",
"description": "Quels sont les symptômes courants de la leucémie ?\nLa perte de poids est-elle un symptôme de leucémie ?\nComment la leucémie affecte-t-elle le système immunitaire ?\nLes douleurs osseuses sont-elles liées à la leucémie ?\nLes sueurs nocturnes sont-elles un symptôme ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Complement+Activation&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Leucémies",
"description": "Peut-on prévenir la leucémie ?\nQuels facteurs de risque sont associés à la leucémie ?\nLe tabagisme augmente-t-il le risque de leucémie ?\nLes infections virales peuvent-elles causer la leucémie ?\nL'alimentation joue-t-elle un rôle dans la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Complement+Activation&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Leucémies",
"description": "Quels sont les traitements principaux de la leucémie ?\nLa chimiothérapie est-elle efficace contre toutes les leucémies ?\nQu'est-ce qu'une greffe de moelle osseuse ?\nQuels sont les effets secondaires de la chimiothérapie ?\nLa radiothérapie est-elle utilisée pour traiter la leucémie ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Complement+Activation&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Leucémies",
"description": "Quelles sont les complications possibles de la leucémie ?\nComment la leucémie affecte-t-elle la coagulation sanguine ?\nLes leucémies peuvent-elles entraîner des problèmes cardiaques ?\nQuelles infections sont fréquentes chez les patients leucémiques ?\nLes leucémies peuvent-elles causer des douleurs chroniques ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Complement+Activation&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Leucémies",
"description": "Quels sont les principaux facteurs de risque de leucémie ?\nL'âge influence-t-il le risque de leucémie ?\nLes troubles génétiques augmentent-ils le risque ?\nLe sexe joue-t-il un rôle dans le risque de leucémie ?\nLes antécédents de chimiothérapie augmentent-ils le risque ?",
"url": "https://questionsmedicales.fr/mesh/D007938?mesh_terms=Complement+Activation&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on une leucémie ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des analyses sanguines, une biopsie de moelle osseuse et des examens d'imagerie."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour confirmer une leucémie ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'hémogramme, la cytométrie en flux et les tests génétiques."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une leucémie lors des tests ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une augmentation des globules blancs, une anémie et des plaquettes basses peuvent indiquer une leucémie."
}
},
{
"@type": "Question",
"name": "Les examens d'imagerie sont-ils nécessaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens comme la radiographie ou l'IRM peuvent aider à évaluer l'extension de la maladie."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la biopsie médullaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie médullaire permet d'évaluer la présence de cellules leucémiques dans la moelle osseuse."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de la leucémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fatigue, fièvre, infections fréquentes et saignements faciles."
}
},
{
"@type": "Question",
"name": "La perte de poids est-elle un symptôme de leucémie ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une perte de poids inexpliquée peut être un symptôme de leucémie."
}
},
{
"@type": "Question",
"name": "Comment la leucémie affecte-t-elle le système immunitaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La leucémie affaiblit le système immunitaire, rendant le corps plus vulnérable aux infections."
}
},
{
"@type": "Question",
"name": "Les douleurs osseuses sont-elles liées à la leucémie ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des douleurs osseuses peuvent survenir en raison de l'accumulation de cellules leucémiques."
}
},
{
"@type": "Question",
"name": "Les sueurs nocturnes sont-elles un symptôme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les sueurs nocturnes peuvent être un symptôme courant chez les patients leucémiques."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la leucémie ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention garantie, mais éviter les facteurs de risque peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à la leucémie ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'exposition aux radiations, certains produits chimiques et des maladies génétiques."
}
},
{
"@type": "Question",
"name": "Le tabagisme augmente-t-il le risque de leucémie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque connu pour certains types de leucémie."
}
},
{
"@type": "Question",
"name": "Les infections virales peuvent-elles causer la leucémie ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections virales, comme le virus d'Epstein-Barr, sont liées à un risque accru de leucémie."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut contribuer à la santé générale, mais ne prévient pas spécifiquement la leucémie."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements principaux de la leucémie ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chimiothérapie, la radiothérapie et la greffe de moelle osseuse."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle efficace contre toutes les leucémies ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chimiothérapie est efficace pour de nombreux types de leucémie, mais pas tous."
}
},
{
"@type": "Question",
"name": "Qu'est-ce qu'une greffe de moelle osseuse ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un traitement qui remplace la moelle osseuse malade par des cellules souches saines."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires de la chimiothérapie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, fatigue, perte de cheveux et infections."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée pour traiter la leucémie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la radiothérapie peut être utilisée pour traiter certaines leucémies, surtout en cas de complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles de la leucémie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent infections graves, saignements, et complications liées aux traitements."
}
},
{
"@type": "Question",
"name": "Comment la leucémie affecte-t-elle la coagulation sanguine ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La leucémie peut entraîner des troubles de la coagulation, augmentant le risque de saignements."
}
},
{
"@type": "Question",
"name": "Les leucémies peuvent-elles entraîner des problèmes cardiaques ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains traitements de la leucémie peuvent augmenter le risque de problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Quelles infections sont fréquentes chez les patients leucémiques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les infections bactériennes et fongiques sont courantes en raison d'un système immunitaire affaibli."
}
},
{
"@type": "Question",
"name": "Les leucémies peuvent-elles causer des douleurs chroniques ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les douleurs chroniques peuvent survenir en raison de la maladie ou des traitements."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque de leucémie ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux facteurs incluent l'exposition aux radiations, certains produits chimiques et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de leucémie ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de leucémie augmente avec l'âge, surtout après 60 ans."
}
},
{
"@type": "Question",
"name": "Les troubles génétiques augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles comme le syndrome de Down augmentent le risque de leucémie."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans le risque de leucémie ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les hommes ont généralement un risque plus élevé de leucémie que les femmes."
}
},
{
"@type": "Question",
"name": "Les antécédents de chimiothérapie augmentent-ils le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avoir reçu une chimiothérapie pour un autre cancer peut augmenter le risque de leucémie."
}
}
]
}
]
}
└─
Leucémie myéloïde
Leukemia, Myeloid
D007951
-
C04.557.337.539
└─└─
Leucémie aigüe myéloïde
Leukemia, Myeloid, Acute
D015470
-
C04.557.337.539.275
└─└─
Leucémie aigüe myélomonocytaire
Leukemia, Myelomonocytic, Acute
D015479
-
C04.557.337.539.520
└─└─└─
Leucémie aiguë à basophiles
Leukemia, Basophilic, Acute
D015471
-
C04.557.337.539.275.125
└─└─└─
Leucémie aigüe à éosinophiles
Leukemia, Eosinophilic, Acute
D015472
-
C04.557.337.539.275.300
└─└─└─
Leucémie aigüe mégacaryoblastique
Leukemia, Megakaryoblastic, Acute
D007947
-
C04.557.337.539.275.450
└─└─└─
Leucémie aigüe monoblastique
Leukemia, Monocytic, Acute
D007948
-
C04.557.337.539.275.484
└─└─└─
Leucémie aiguë promyélocytaire
Leukemia, Promyelocytic, Acute
D015473
-
C04.557.337.539.275.700
Chronic antibody-mediated rejection in kidney transplantation is a common cause of graft loss in the late post-transplant period. In this process, the role of the classical complement activation pathw...
Due to technological advancements, surgical invasiveness has been reduced. However, cataract surgery has been implicated in causing postoperative inflammation, including dry eye syndrome. The innate i...
Forty-three patients (23 women; median age, 69 years) were enrolled in this prospective study and underwent phacoemulsification and vitrectomy. We measured Schirmer's test (ST) and CAPs in the tears a...
The median ST (8.5 mm) at baseline increased to 16 mm at 4 days ( P < 0.001) and 10 mm at 1 month (P = 0.44). The C3a levels (1202 pg/ml) at baseline increased to 2753 pg/ml at 4 days (P < 0.001), and...
The CAPs levels in tears increased after vitrectomy combined with cataract surgery. A preoperative deficit in tear secretion might induce prolonged complement activation and delayed recovery of ocular...
Complement component 5 (C5) targeting therapies are clinically beneficial in patients with acetylcholine receptor antibody...
In a case-control study, concentrations of C3a, C5a and sC5b9 were simultaneously quantified, indicating general activation of the complement system, whether via the classical and lectin pathways (C4a...
Treatment-naïve patients with AChR-Ab...
Markers indicative of complement activation are prominently increased in patients with AChR-Ab MG despite standard immunosuppressive therapies. Complement inhibition proximal to C5 cleavage should be ...
The complement system is a key component of the innate immune system, and its aberrant activation underlies the pathophysiology of various diseases. Zilucoplan is a macrocyclic peptide that binds and ...
The interaction of zilucoplan with C5, including for clinical C5 R885 variants, was investigated using surface plasmon resonance (SPR), hemolysis assays, and ELISA. The interference of C5b6 formation ...
Zilucoplan specifically bound human complement C5 with high affinity, competitively inhibited the binding of C5 to C3b, and blocked C5 cleavage by C5 convertases and the assembly of the cytolytic memb...
Our findings demonstrate that zilucoplan uses a dual mode of action to potently inhibit the activation of C5 and terminal complement pathway including wild-type and clinical R885 variants that do not ...
Transplant-associated thrombotic microangiopathy remains a lethal complication of haematopoietic stem cell transplant and not all patients respond to terminal complement inhibitors. Qi et al. show tha...
The intravascular formation of neutrophil extracellular traps (NETs) is a trigger for coagulation and blood vessel occlusion. NETs are released from neutrophils as a response to strong inflammatory si...
In the present study, we used different microfluidic setups in combination with fluorescence microscopy to investigate the influence of neutrophil-derived extracellular DNA fibers on blood rheology, i...
We found that extended DNA fiber networks decelerate blood flow and promote intravascular occlusion of blood vessels independent of the plasmatic coagulation. Associated with the DNA dependent occlusi...
In conclusion, we found that DNA fibers as the principal component of NETs are sufficient to induce blood aggregation even in the absence of the coagulation system. Moreover, we discovered that comple...
Hidradenitis suppurativa (HS) is a chronic auto-inflammatory skin disease with a complex and multifactorial pathogenesis involving both the innate and adaptive immune system. Despite limited evidence ...
Sepsis is characterized by a dysregulated immune response to infection. The complement system plays an important role in the host defence to pathogens. However, exaggerated complement activation might...
Secondary analysis of complement factors in a prospective study in 209 hospitalized sepsis patients, of whom the majority presented with shock. Concentrations of complement factors C3, C3a, C3c, C5, C...
The concentration of complement factors in plasma of severely ill sepsis patients indicated profound activation of the complement system (all P < 0.01 compared to healthy controls). Spearman rank corr...
Once an infection progresses to severe sepsis or septic shock, the complement pathway is already profoundly activated and is no longer related to a dysregulated inflammatory response, nor to clinical ...
Complement activation through antibody-antigen complexes is crucial in various pathophysiological processes and utilized in immunotherapies to eliminate infectious agents, regulatory immune cells, or ...
To prepare nanoscale ultrasound contrast agents (Nano-UCAs) and examine the role of their surface charge in complement activation and phagocytosis....
We analyzed serum proteins present in the corona formed on Nano-UCAs and evaluated two important protein markers of complement activation (C3 and SC5b-9). The effect of surface charge on phagocytosis ...
When Nano-UCAs were incubated with human serum, they were opsonized by various blood proteins, especially C3. Highly charged Nano-UCAs, whether positive or negative, were favorably opsonized by comple...
Charged Nano-UCAs show a higher tendency to activated complement system, and are efficiently engulfed by macrophages. The present results provide meaningful insights into the role of the surface charg...